Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME

v3.23.3
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Sep. 30, 2023
Sep. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME    
Net sales $ 276,935 $ 269,655
Cost of sales 91,744 90,060
Gross margin 185,191 179,595
Operating expenses:    
Selling, general and administrative 105,331 99,375
Research and development 23,998 23,903
Total operating expenses 129,329 123,278
Operating income 55,862 56,317
Other income (expense) (6,304) 47,399
Earnings before income taxes 49,558 103,716
Income taxes (benefit) (1,435) 13,982
Net earnings, including noncontrolling interest 50,993 89,734
Net earnings attributable to noncontrolling interest   179
Net earnings attributable to Bio-Techne 50,993 89,555
Other comprehensive income (loss):    
Foreign currency translation adjustments (11,602) (21,457)
Foreign currency translation reclassified to earnings with Eminence deconsolidation   119
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 (350) 4,695
Other comprehensive income (loss) (11,952) (16,643)
Other comprehensive income (loss) attributable to noncontrolling interest   (33)
Other comprehensive income (loss) attributable to Bio-Techne (11,952) (16,610)
Comprehensive income attributable to Bio-Techne $ 39,041 $ 72,945
Earnings per share attributable to Bio-Techne:    
Basic (in dollars per share) $ 0.32 $ 0.57
Diluted (in dollars per share) $ 0.31 $ 0.55
Weighted average common shares outstanding:    
Basic (in shares) 158,130 156,929
Diluted (in shares) 161,940 162,172